{"id":3475,"date":"2018-10-23T17:53:09","date_gmt":"2018-10-23T12:23:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3475"},"modified":"2021-07-24T12:57:06","modified_gmt":"2021-07-24T07:27:06","slug":"notizia-77","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-77","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Novartis comes up with an answer for breast cancer with PI3K drug alpelisib<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Novartis\u00a0<\/strong>comes up with an answer with its recent data on <strong>BYL719 (alpelisib)<\/strong> in combination with <strong>fulvestrant<\/strong>. Their alpha-specific drug for <strong>PIK3CA<\/strong> mutated HR+\/HER2- advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market-insight\">breast cancer<\/a>, BYL719 plus fulvestrant\u00a0nearly doubled the progression-free survival times\u00a0for patients. Around 40% of HR+ advanced breast cancer patients have a PIK3CA mutation, making it a considerable piece for the overall market. \u00a0As the drug is an alpha-specific, so the drug standouts. Also, it has lower toxicity, so, the majority of the patients can be on therapy for a longer time.<\/p>\n<p style=\"text-align: justify;\"><strong>Epizyme files for first FDA filing with tazemetostat update<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Epizyme<\/strong>, a clinical stage biopharmaceutical company based in the US displayed updated data from a <strong>phase 2 trial<\/strong>\u00a0of its lead asset, <strong>tazemetostat<\/strong>, in epithelioid <a href=\"https:\/\/www.delveinsight.com\/report-store\/ewing-sarcoma-market\">sarcoma<\/a>. The data displayed an objective response rate (ORR) of 13% across 62 patients, with treatment-na\u00efve patients\u00a0performing better than relapsed or refractory patients, having an\u00a0ORR of 21% versus 8% respectively.\u00a0The survival and response durability are also imperative in aggressive cancer that has no specific treatments and is often fatal. Epithelioid sarcoma can be\u00a0tough to diagnose\u00a0and hence\u00a0may not be discovered until it is advanced.<\/p>\n<p style=\"text-align: justify;\"><strong>Rheumatoid arthritis<\/strong>\u00a0<strong>of<\/strong> <strong>GlaxoSmithKline slips phase 2 endpoint<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>GlaxoSmithKline<\/strong> has\u00a0missed\u00a0the primary endpoint in a <strong>phase 2 trial<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/juvenile-rheumatoid-arthritis-market\"><strong>rheumatoid arthritis<\/strong><\/a> candidate, <strong>GSK3196165<\/strong>. The highest dose of the <strong>anti-GM-CSF<\/strong> antibody flunked to supersede the placebo on a disease activity score, however, GSK contemplates going ahead with more clinical trials. <strong>GM-CSF<\/strong> is related to the formation of pro-inflammatory <strong>cytokines<\/strong>, <strong>chemokines<\/strong> and <strong>proteases<\/strong> that play a role in the joint destruction. As GM-CSF levels get high in the joints of patients suffering from rheumatoid arthritis, GSK ruminates to target the inflammatory mediator that could disturb the pathways, which lead to articular destruction.<\/p>\n<p style=\"text-align: justify;\"><strong>AstraZeneca and Ionis aim diabetes with antisense approach for pancreatic cells regeneration<\/strong><\/p>\n<p style=\"text-align: justify;\">A progressive loss of insulin-producing beta cells in the pancreas causes <strong>Type 2 diabetes<\/strong>, and present therapies cannot do much, but relieving symptoms. So, <strong>AstraZeneca<\/strong> and <strong>Ionis<\/strong> are in collaboration to investigate a novel way to aim beta cells with <strong>antisense oligonucleotides (ASOs<\/strong>)-the approach that may aid in the restoration of the functioning of those vital cells. Basically, ASOs are synthetic polymers designed to aim RNA and modify the disease-causing proteins production.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis\u00a0comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+\/HER2- advanced breast cancer, BYL719 plus fulvestrant\u00a0nearly doubled the progression-free survival times\u00a0for patients. Around 40% of HR+ advanced breast cancer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3261,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2021,2025,2026,96,2015,1867,2016,985,2022,2020,2018,2024,423,2017,2019,1866,2023],"industry":[17225],"therapeutic_areas":[17240,17227,17228],"class_list":["post-3475","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anti-gm-csf","tag-antisense-oligonucleotides-asos","tag-aso","tag-astrazeneca","tag-byl719-alpelisib","tag-epizyme","tag-fulvestrant","tag-glaxosmithkline","tag-gm-csf","tag-gsk3196165","tag-hr-her2-advanced-breast-cancer","tag-ionis","tag-novartis","tag-pik3ca","tag-rheumatoid-arthritis","tag-tazemetostat","tag-type-2-diabetes","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 23\/10\/2018 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"Novartis\u00a0comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-77\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 23\/10\/2018 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"Novartis\u00a0comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-77\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-23T12:23:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"305\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 23\/10\/2018 - DelveInsight Business Research LLP","description":"Novartis\u00a0comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-77","og_locale":"en_US","og_type":"article","og_title":"Notizia 23\/10\/2018 - DelveInsight Business Research LLP","og_description":"Novartis\u00a0comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for.....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-77","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-10-23T12:23:09+00:00","article_modified_time":"2021-07-24T07:27:06+00:00","og_image":[{"width":466,"height":305,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-77","url":"https:\/\/www.delveinsight.com\/blog\/notizia-77","name":"Notizia 23\/10\/2018 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-77#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-77#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","datePublished":"2018-10-23T12:23:09+00:00","dateModified":"2021-07-24T07:27:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Novartis\u00a0comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-77"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-77#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305.jpg","width":466,"height":305,"caption":"Companion Diagnostics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09022444\/DNA_med_coverLG_opt-466x305-300x196.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">anti-GM-CSF<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">antisense oligonucleotides (ASOs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ASO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BYL719 (alpelisib)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epizyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">fulvestrant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GM-CSF<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK3196165<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HR+\/HER2- advanced breast cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ionis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PIK3CA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tazemetostat<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 2 diabetes<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">anti-GM-CSF<\/span>","<span class=\"advgb-post-tax-term\">antisense oligonucleotides (ASOs<\/span>","<span class=\"advgb-post-tax-term\">ASO<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">BYL719 (alpelisib)<\/span>","<span class=\"advgb-post-tax-term\">Epizyme<\/span>","<span class=\"advgb-post-tax-term\">fulvestrant<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">GM-CSF<\/span>","<span class=\"advgb-post-tax-term\">GSK3196165<\/span>","<span class=\"advgb-post-tax-term\">HR+\/HER2- advanced breast cancer<\/span>","<span class=\"advgb-post-tax-term\">Ionis<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">PIK3CA<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>","<span class=\"advgb-post-tax-term\">tazemetostat<\/span>","<span class=\"advgb-post-tax-term\">Type 2 diabetes<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 23, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 23, 2018 5:53 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3475"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3261"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3475"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3475"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}